Hemagen Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Begins initial public offering of 1 mil. shares of common stock at $5 per share, with an expected net of $4 mil. The Waltham, Massachusetts-based manufacturer of autoimmune disease test kits filed a preliminary registration statement with the Securities and Exchange Commission in September ("The Gray Sheet" Nov. 2, p. 16). Reich & Co. is underwriting.